JP2020513404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513404A5 JP2020513404A5 JP2019529476A JP2019529476A JP2020513404A5 JP 2020513404 A5 JP2020513404 A5 JP 2020513404A5 JP 2019529476 A JP2019529476 A JP 2019529476A JP 2019529476 A JP2019529476 A JP 2019529476A JP 2020513404 A5 JP2020513404 A5 JP 2020513404A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antagonist
- amino acid
- acid sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022132878A JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
| JP2023148026A JP2023175785A (ja) | 2016-12-01 | 2023-09-13 | 炎症性状態の処置方法 |
| JP2025167062A JP2026016421A (ja) | 2016-12-01 | 2025-10-03 | 炎症性状態の処置方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428634P | 2016-12-01 | 2016-12-01 | |
| US62/428,634 | 2016-12-01 | ||
| US201762473738P | 2017-03-20 | 2017-03-20 | |
| US62/473,738 | 2017-03-20 | ||
| US201762567318P | 2017-10-03 | 2017-10-03 | |
| US62/567,318 | 2017-10-03 | ||
| PCT/US2017/064041 WO2018102597A1 (en) | 2016-12-01 | 2017-11-30 | Methods of treating inflammatory conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132878A Division JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513404A JP2020513404A (ja) | 2020-05-14 |
| JP2020513404A5 true JP2020513404A5 (https=) | 2021-01-07 |
| JP7132220B2 JP7132220B2 (ja) | 2022-09-06 |
Family
ID=60788696
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529476A Active JP7132220B2 (ja) | 2016-12-01 | 2017-11-30 | 炎症性状態の処置方法 |
| JP2022132878A Active JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
| JP2023148026A Pending JP2023175785A (ja) | 2016-12-01 | 2023-09-13 | 炎症性状態の処置方法 |
| JP2025167062A Pending JP2026016421A (ja) | 2016-12-01 | 2025-10-03 | 炎症性状態の処置方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132878A Active JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
| JP2023148026A Pending JP2023175785A (ja) | 2016-12-01 | 2023-09-13 | 炎症性状態の処置方法 |
| JP2025167062A Pending JP2026016421A (ja) | 2016-12-01 | 2025-10-03 | 炎症性状態の処置方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10815305B2 (https=) |
| EP (1) | EP3548513A1 (https=) |
| JP (4) | JP7132220B2 (https=) |
| KR (3) | KR102645242B1 (https=) |
| CN (2) | CN110167963B (https=) |
| AU (2) | AU2017367691B2 (https=) |
| BR (1) | BR112019010646A2 (https=) |
| CA (1) | CA3044851A1 (https=) |
| CL (1) | CL2019001475A1 (https=) |
| CO (1) | CO2019005236A2 (https=) |
| CR (1) | CR20190311A (https=) |
| IL (1) | IL266770B2 (https=) |
| MA (1) | MA46954A (https=) |
| MX (2) | MX2019006177A (https=) |
| MY (1) | MY200433A (https=) |
| NZ (2) | NZ794842A (https=) |
| PH (1) | PH12019501120A1 (https=) |
| TN (1) | TN2019000172A1 (https=) |
| TW (2) | TWI784988B (https=) |
| UA (1) | UA127965C2 (https=) |
| WO (1) | WO2018102597A1 (https=) |
| ZA (1) | ZA201903091B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| MX2019012171A (es) | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| CA3079946A1 (en) * | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| KR20240132386A (ko) | 2017-12-29 | 2024-09-03 | 코넬 유니버시티 | 호산구성 장애에 대한 유전자 요법 |
| WO2019198703A1 (ja) | 2018-04-10 | 2019-10-17 | 日立化成株式会社 | エポキシ樹脂、エポキシ樹脂組成物、エポキシ樹脂硬化物及び複合材料 |
| IL307286B2 (en) | 2018-04-11 | 2026-03-01 | Regeneron Pharma | Methods and reagents for IL-33 quantification |
| US11312778B2 (en) | 2018-11-21 | 2022-04-26 | Brian C. Machler | Method for treating allergic contact dermatitis |
| CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| CN113557036A (zh) | 2019-01-18 | 2021-10-26 | 奥泽生物疗法公司 | 基因编辑以改善关节功能 |
| TW202519263A (zh) | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| US20210000949A1 (en) * | 2019-05-01 | 2021-01-07 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| WO2021068196A1 (en) * | 2019-10-11 | 2021-04-15 | General Regeneratives (Shanghai) Limited | Methods of using il-33 protein in treating cancers |
| IL292442A (en) * | 2019-11-04 | 2022-06-01 | Medimmune Ltd | Anti-il-33 therapeutic agent for the treatment of kidney disorders |
| AU2020398168A1 (en) * | 2019-12-06 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods for treating COPD by administering an IL-33 antagonist |
| EP4081544A1 (en) * | 2019-12-23 | 2022-11-02 | Sanofi Biotechnology | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist |
| US20230110203A1 (en) | 2020-03-13 | 2023-04-13 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| EP4132972A1 (en) | 2020-04-06 | 2023-02-15 | MedImmune Limited | Treating acute respiratory distress syndrome with il-33 axis binding antagonists |
| CN113527485B (zh) * | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| CN113549151A (zh) * | 2020-04-24 | 2021-10-26 | 苏州康乃德生物医药有限公司 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
| JP7578943B2 (ja) * | 2020-07-13 | 2024-11-07 | 学校法人自治医科大学 | 褥瘡治療剤 |
| CN111714619B (zh) * | 2020-07-15 | 2023-03-14 | 上海市浦东新区人民医院 | 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用 |
| KR20230123981A (ko) * | 2020-12-23 | 2023-08-24 | 누맙 세러퓨틱스 아게 | Il-4r에 결합하는 항체 가변 도메인 |
| CN117858898A (zh) * | 2021-08-27 | 2024-04-09 | 免疫医疗有限公司 | 用抗白介素-33抗体治疗慢性阻塞性肺病 |
| CA3236201A1 (en) * | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33) |
| JP7544228B2 (ja) | 2022-10-31 | 2024-09-03 | トヨタ自動車株式会社 | 車両制御システム、車両製造方法、プログラム及び情報処理装置 |
| CN121079320A (zh) * | 2023-02-28 | 2025-12-05 | 科达制药股份有限公司 | 多价trap-抗体融合体 |
| CN120118185B (zh) * | 2025-03-11 | 2025-08-26 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种猫过敏原Fel d 1蛋白单克隆抗体及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| JPH06510750A (ja) | 1991-05-03 | 1994-12-01 | セラジェン インク | 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子 |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| RU2162711C2 (ru) | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
| US5576191A (en) | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
| ATE326239T1 (de) | 1998-09-18 | 2006-06-15 | Dynavax Tech Corp | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
| US20050031609A1 (en) | 2001-05-11 | 2005-02-10 | Thomas Hultsch | Compositions for use in treating ige-associated disorders |
| CA2447795A1 (en) | 2001-05-23 | 2002-11-28 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| PT1527100E (pt) | 2002-03-29 | 2009-08-25 | Schering Corp | Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos |
| US20070042978A1 (en) | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
| WO2004070011A2 (en) | 2003-02-01 | 2004-08-19 | Tanox, Inc. | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| BRPI0416603A (pt) | 2003-11-07 | 2007-01-30 | Immunex Corp | anticorpo que se liga ao receptor interleucina-4 (il-4) humano |
| AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| EP1723173B1 (en) | 2004-02-27 | 2008-05-14 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 specific polypeptides and therapeutic uses thereof |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
| KR101443050B1 (ko) | 2005-05-06 | 2014-09-22 | 지모제넥틱스, 인코포레이티드 | Ｉｌ-31 단클론성 항체 및 사용법 |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8865645B2 (en) | 2006-05-24 | 2014-10-21 | Biogen Idec Ma Inc. | Method of treating lung fibrosis using ST2 polypeptide |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
| MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
| WO2008144610A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
| EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| WO2009053098A1 (en) | 2007-10-26 | 2009-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders |
| WO2009061819A1 (en) | 2007-11-05 | 2009-05-14 | The Regents Of The University Of Colorado | Minimally-invasive measurement of esophageal inflammation |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| AU2009322556A1 (en) | 2008-12-01 | 2011-07-21 | Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
| US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
| CN107320722A (zh) | 2009-09-07 | 2017-11-07 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| EP3970726A1 (en) | 2010-06-24 | 2022-03-23 | ViroPharma Biologics LLC | Methods of treatment for esophageal inflammation |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| EP2661631A4 (en) | 2011-01-06 | 2014-05-21 | Childrens Hosp Medical Center | EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS |
| EP2678358B1 (en) | 2011-02-23 | 2015-07-22 | F.Hoffmann-La Roche Ag | Antibodies against human il33r and uses thereof |
| US9928344B2 (en) | 2011-06-21 | 2018-03-27 | Children's Hospital Medical Center | Diagnostic methods of eosinophilic esophagitis |
| CN103974706A (zh) | 2011-10-06 | 2014-08-06 | N·V·努特里奇亚 | 嗜酸细胞性食管炎的治疗 |
| WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| US9574004B2 (en) * | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| PT3889181T (pt) | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EP2968454B1 (en) * | 2013-03-15 | 2019-02-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| CN111437387B (zh) * | 2013-06-21 | 2024-10-01 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| EP3088517B1 (en) | 2013-12-26 | 2023-11-01 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| ES2866935T3 (es) | 2014-01-10 | 2021-10-20 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (IL-33) |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| NO2785538T3 (https=) * | 2014-05-07 | 2018-08-04 | ||
| CR20170240A (es) | 2014-11-10 | 2018-04-03 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos |
| JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Ｉｌ－３３媒介性障害のための治療及び診断方法 |
| HRP20210096T1 (hr) | 2015-03-31 | 2021-03-05 | Medimmune Limited | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
-
2017
- 2017-11-29 TW TW106141530A patent/TWI784988B/zh active
- 2017-11-29 TW TW111142355A patent/TWI857389B/zh active
- 2017-11-30 TN TNP/2019/000172A patent/TN2019000172A1/en unknown
- 2017-11-30 AU AU2017367691A patent/AU2017367691B2/en active Active
- 2017-11-30 KR KR1020197015123A patent/KR102645242B1/ko active Active
- 2017-11-30 BR BR112019010646A patent/BR112019010646A2/pt unknown
- 2017-11-30 CR CR20190311A patent/CR20190311A/es unknown
- 2017-11-30 NZ NZ794842A patent/NZ794842A/en unknown
- 2017-11-30 CA CA3044851A patent/CA3044851A1/en active Pending
- 2017-11-30 JP JP2019529476A patent/JP7132220B2/ja active Active
- 2017-11-30 KR KR1020257007692A patent/KR20250040088A/ko active Pending
- 2017-11-30 WO PCT/US2017/064041 patent/WO2018102597A1/en not_active Ceased
- 2017-11-30 UA UAA201907159A patent/UA127965C2/uk unknown
- 2017-11-30 MY MYPI2019002952A patent/MY200433A/en unknown
- 2017-11-30 EP EP17818689.6A patent/EP3548513A1/en active Pending
- 2017-11-30 NZ NZ754300A patent/NZ754300A/en unknown
- 2017-11-30 MA MA046954A patent/MA46954A/fr unknown
- 2017-11-30 US US15/827,357 patent/US10815305B2/en active Active
- 2017-11-30 IL IL266770A patent/IL266770B2/en unknown
- 2017-11-30 MX MX2019006177A patent/MX2019006177A/es unknown
- 2017-11-30 CN CN201780073449.2A patent/CN110167963B/zh active Active
- 2017-11-30 KR KR1020247007290A patent/KR102780485B1/ko active Active
- 2017-11-30 CN CN202410698813.6A patent/CN118662629A/zh active Pending
-
2019
- 2019-05-17 ZA ZA2019/03091A patent/ZA201903091B/en unknown
- 2019-05-20 PH PH12019501120A patent/PH12019501120A1/en unknown
- 2019-05-22 CO CONC2019/0005236A patent/CO2019005236A2/es unknown
- 2019-05-28 MX MX2023008368A patent/MX2023008368A/es unknown
- 2019-05-30 CL CL2019001475A patent/CL2019001475A1/es unknown
-
2020
- 2020-09-22 US US17/028,011 patent/US11866503B2/en active Active
-
2022
- 2022-08-24 JP JP2022132878A patent/JP7351989B2/ja active Active
-
2023
- 2023-09-13 JP JP2023148026A patent/JP2023175785A/ja active Pending
- 2023-11-29 US US18/523,048 patent/US20240209102A1/en active Pending
-
2024
- 2024-12-10 AU AU2024278257A patent/AU2024278257A1/en active Pending
-
2025
- 2025-10-03 JP JP2025167062A patent/JP2026016421A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513404A5 (https=) | ||
| JP2018533557A5 (https=) | ||
| JP7454882B2 (ja) | 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用 | |
| KR102307248B1 (ko) | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 | |
| EP2627673B1 (en) | Therapies for improving pulmonary function | |
| JP2019531273A5 (https=) | ||
| JP2020513404A (ja) | 炎症性状態の処置方法 | |
| Grainge et al. | Targeted therapeutics for severe refractory asthma: monoclonal antibodies | |
| JP2019534282A (ja) | 抗ｉｌ−３３抗体およびその使用 | |
| RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
| RU2016134838A (ru) | Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком | |
| JP2025122028A (ja) | Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 | |
| JP2026068738A (ja) | Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 | |
| JP7458790B2 (ja) | Ｉｌ－６阻害剤を含有する喘息の治療剤 | |
| Hartley et al. | Severe asthma: novel advances in the pathogenesis and therapy | |
| TW202317622A (zh) | 以ｓｔ２拮抗劑治療慢性阻塞性肺病的方法 | |
| JP2025164767A (ja) | Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 | |
| JP6663910B2 (ja) | 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法 | |
| US11156600B2 (en) | Assay for detecting TH1 and TH2 cell populations | |
| CN114423455A (zh) | 用于治疗系统性硬化症的药物组合物 | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| Leung et al. | Emerging treatment options in severe asthma | |
| Seymour et al. | Intervention in Severe Eosinophilic | |
| WP_Seymour et al. | Navigating the Terrain: Type 2 Cytokines and Biologic Intervention in Severe Eosinophilic Asthma | |
| WO2024146630A1 (zh) | 一种tslp抗体治疗哮喘的方法 |